Neumora Therapeutics (NMRA) Operating Income (2022 - 2026)
Neumora Therapeutics (NMRA) posted quarterly Operating Income of -$52.9 million for Q1 2026, up 25.48% year-over-year from -$42.1 million in Q1 2025, and up 9.6% quarter-over-quarter from -$58.5 million in Q4 2025.
Neumora Therapeutics (NMRA) Operating Income (2022 - 2026) Analysis & Trends
Neumora Therapeutics' Operating Income history runs 5 years deep, the most recent figure standing at -$52.9 million for Q1 2026.
- In Q1 2026, Operating Income rose 25.48% year-over-year to -$52.9 million; the TTM figure through Mar 2026 stood at -$223.1 million (up 18.68% YoY), while the FY2025 annual figure was -$241.2 million, up 8.47% from the prior year.
- Operating Income for Q1 2026 stood at -$52.9 million, up from -$58.5 million in the prior quarter.
- The five-year high for Operating Income was -$30.6 million in Q3 2022, with the low at -$114.0 million in Q4 2023.
- The 5-year median for Operating Income is -$57.7 million (2025), against an average of -$58.1 million.
- The sharpest annual moves came in 2023 and 2024: Operating Income plunged 271.13% in 2023, then surged 44.81% in 2024.
- Neumora Therapeutics' Operating Income stood at -$30.7 million in 2022, then slumped by 271.13% to -$114.0 million in 2023, then soared by 44.81% to -$62.9 million in 2024, then advanced by 7.06% to -$58.5 million in 2025, then increased by 9.6% to -$52.9 million in 2026.
- Business Quant data shows NMRA's Operating Income at -$52.9 million in Q1 2026, -$58.5 million in Q4 2025, and -$57.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,158.03 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Neumora Therapeutics | 296.45 Mn | 296.45 Mn | - | -52.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -52.86 Mn |
| Dec 31, 2025 | -58.48 Mn |
| Sep 30, 2025 | -57.70 Mn |
| Jun 30, 2025 | -54.04 Mn |
| Mar 31, 2025 | -70.94 Mn |
| Dec 31, 2024 | -62.92 Mn |
| Sep 30, 2024 | -76.65 Mn |
| Jun 30, 2024 | -63.82 Mn |
| Mar 31, 2024 | -60.07 Mn |
| Dec 31, 2023 | -114.00 Mn |
| Sep 30, 2023 | -56.86 Mn |
| Jun 30, 2023 | -42.06 Mn |
| Mar 31, 2023 | -39.17 Mn |
| Dec 31, 2022 | -30.72 Mn |
| Sep 30, 2022 | -30.60 Mn |